AI assistant
HERON THERAPEUTICS, INC. /DE/ — Director's Dealing 2018
Oct 3, 2018
33572_dirs_2018-10-02_3712dd60-72ce-4d92-b6dd-4ed16cbbe4d5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK: 0000818033
Period of Report: 2018-10-01
Reporting Person: MANHARD KIMBERLY (Executive VP, Drug Development)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-10-01 | Common Stock | M | 6000 | $13.00 | Acquired | 6000 | Direct |
| 2018-10-01 | Common Stock | S | 6000 | $32.0722 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-10-01 | Employee Stock Option (Right to Buy) | $13.00 | M | 6000 | Disposed | 2026-12-21 | Common Stock (6000) | Direct |
Footnotes
F1: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018.
F2: The range of sales prices received was $31.75 to $32.38. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
F3: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (12/21/2016).